Andy Gould

From fees to yield to risk, these two mining ETFs take sharply different paths -- see how their unique profiles could fit your portfolio goals.

Expense ratios, diversification strategies, and dividend payouts set these two consumer staples ETFs apart.

Expense ratios, sector mix, and yield set these funds apart -- here's how their strategies could fit different portfolio goals.

Explore the minor differences between these two nearly identical consumer staples ETFs.

Expense ratios, yield, and diversification set these two consumer staples ETFs apart -- see which fund is the best fit for your portfolio.

Explore how differing portfolio strategies and fees set these two consumer staples ETFs apart for long-term investors.

Focused on therapies for rare blood disorders, this biotech saw a notable insider sale amid ongoing clinical development efforts.

Operating in grid-scale energy storage, this battery innovator saw a notable insider buy after shares tanked post-earnings.

Interface, Inc., a global modular flooring company, reported a series of insider sales over four consecutive trading days in early March 2026.

Explore how differences in holdings, yield, and fund size could impact your choice between these two core U.S. market ETFs.

Explore how differences in sector coverage, risk, and cost between these two ETFs could impact your technology investing strategy.

This integrated downstream energy company reported notable insider selling across two recent SEC filings.

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale after a strong one-year stock performance.

As a major operator in global energy shipping, International Seaways reported a significant insider sale amid robust share price gains.

Collegium Pharmaceutical, a leader in abuse-deterrent pain therapies, saw its Chief Commercial Officer trim his stake by more than 40%.

Visteon, a leader in automotive electronics and cockpit solutions, reported a significant insider sale this month.

Focused on therapies for rare skin diseases, this clinical-stage biotech saw a notable director purchase coincide with a decisive Phase 3 trial announcement and the closing of a $230 million equity offering.

This blockchain-focused lender saw a notable insider sale as it continues to expand its digital finance offerings.

Core Scientific delivers digital asset mining and blockchain infrastructure services for institutional clients across North America.

This Indiana-based regional bank has seen a notable burst of insider buying activity -- with a director making three separate open-market purchases in February and March.